Pharmaceutical Price Controls in the Oecd Countries

Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation U.S. Department of Commerce International Trade Administration The International Trade Administration (ITA) has as its mission the creation of economic opportunity for U.S. workers and firms by promoting international trade, opening foreign markets, ensuring compliance with trade laws and agreements, and supporting U.S. commercial interests at home and abroad. To learn more about the ITA, write to: International Trade Administration, Office of Public Affairs, U.S. Department of Commerce, Washington, DC 20230, or visit the ITA’s Internet site at www.ita.doc.gov. Pharmaceutical Price Controls in OECD†¦show more content†¦Department of Commerce, International Trade Administration Executive Summary Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (RD). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation andShow MoreRelatedPharmaceutical Industry : United Kingdom, Usa Essay1628 Words   |  7 Pagesthe main hub of pharmaceutical industry are in United Kingdom, USA. New Zealand is far away located from these countries and has a population of 4.4 million and has got less number of pharmaceutical industries. The statistics figure show that there were only two compounds developed during 2001 but due to increased in the government funds from $16.3 million in the year 2000-2001 to $43.1 million in the year 2006-2007 the number increased to 12. The success and profit of a pharmaceutical industry dependsRead MoreU.s. Health Care System Es say1600 Words   |  7 PagesWhat is the real and perceived performance of the U.S. health care system? Are the views different among patients, providers, payers, and policy makers? Why or why not? According to Kovner and Knickman (2011), acutely ill patients within the country may hold a positive view of the country’s healthcare system, as the U.S. is scientifically and technology advanced in treating life-threatening injuries and illnesses. Overall quality of healthcare performance, however, is lacking (Kovner KnickmanRead MoreCanadian Drug Coverage940 Words   |  4 PagesAddressing Gaps in Canadian Drug Coverage According to Morgan and Boothe (2016), Canadas medicare system is the only one among developed countries that has universal public health insurance but does not also have universal prescription drug coverage. The amount of out-of-pocket (OOP) spending is an immense burden for many Canadians, accounting for 34.3% of private expenditures, (Hennessey et al., 2016); and in Ontario, one in three people do not have employer-provided health insurance (Barnes Read MoreWhat Is The Power Of Rising Pharmaceutical Prices In The United States?700 Words   |  3 Pagesrealm, yet there is a great discrepancy between the price of health care and the quality of such. In addition, an abundance of evidence shows that this modern nation currently spends 18% of its GDP on health care, where the majority is comprised of private expenditures (OECD 2015). The private sector of health spending, in particular, is of great interest, because 17% of total healthcare costs is attributed to prescription drugs. Ph armaceutical companies in the U.S justify excessive costs for medicationRead MoreWhat Is Political Action For Universal Drug Care934 Words   |  4 PagesAddressing Gaps in Canadian Pharmacare According to Morgan and Boothe (2016), Canadas Medicare system is the only one among the developed countries that has universal public health insurance but does not also have universal prescription drug coverage. The amount of out-of-pocket (OOP) spending can become a great burden on Canadians, as private insurance â€Å"only composes approximately 34.3% of expenditures,† (Hennessey et al., 2016); and in Ontario, 1 in 3 people do not have employer-provided healthRead MoreBiotechnology Industry Analysis1121 Words   |  5 Pagesthe price. The producer can set a high price to cover the huge RD costs and gain high profits. The annual report of the two company showed that the EBITDA of CSL and COH are 1350.3 million dollars and 236.6 million dollars in June 2011. However, the buy power can be a bit lower. According to the study of U.S. Department of Commerce International Trade Administration (2004), in the Organization for Economic Cooperation and Development (OECD) countries su ch as Australia, have the price control on theRead MoreUs Health Care System With Oecd1355 Words   |  6 PagesComparison of US health care system with OECD Referring to the health care performance analysis done by the commonwealth fund (put a reference), the US health care system consistently fails to achieve the balance between the service provided and the expenditure incurred. Although the U.S. spends more on health care than any other country and has the highest proportion of specialist physicians, survey findings indicate that from the patients perspective, and based on outcome indicators, the performanceRead MoreAdequate Measurement Of The Patient Protection And Affordable Care Act1227 Words   |  5 PagesDevelopment (OECD), pertaining to data from 2006, it is notable that of 30 industrialized counties measured, the U.S. health care spending was significantly higher, both per capita and as a gross domestic product (Anderson Squires, p. 1-2). In The Commonwealth Fund issues that have been publicized since are dated in 2013 and 2014, where data from 2011 is analyzed. In the five years that has passed, spending in the U.S. has still been higher than in any other industrialized country. However, spendingRead MoreWhat Is The Medicare Drug Price Negotiation Act?1494 Words   |  6 PagesBackground The Medicare Drug Price Negotiation Act (S. 2011) would amend Title XVIII of the Social Security Act to allow for the negotiation of drug prices on behalf of Medicare beneficiaries for those medications covered under Medicare Part D. The policy would be enacted at the federal level, and the policy tool used to do so would be federal funding. Under this bill, the Secretary of the Department of Health and Human Services (DHHS) would be given the power to negotiate drug prices as well as establishRead MoreThe New Zealand Healthcare System Essay1298 Words   |  6 Pagesits GDP on the health care industry. This represents nearly double the amount spent by other OECD nations (an average of 8.7%) and came in 40 percent higher than the next highest nation, France, which had an 11.2% of GDP outlays on health care expenditures. If we examine these costs at an individual level the US spent $7,538 per capita (per person) on health care. This was more than double the OECD median for expen ditures which was $2,995. Again the next highest nations were considerably less